From: Outcomes of metastasis-directed therapy of bone oligometastatic prostate cancer
Imaging method prior to MDT, n (%) | Â |
---|---|
PSMA-PET/CT | 73 (91.3%) |
Choline-PET/CT | 3 (3.8%) |
Bone scan with or without CT/MRI, n (%) | 4 (5.0%) |
PSA at imaging (ng/ml), median (range) | 1.24 (0.07–1252) |
Number of metastases, n (%) | |
 One metastasis | 53 (66.3%) |
 Two metastases | 20 (25.0%) |
 Three metastases | 6 (7.5%) |
 Four metastases | 1 (1.3%) |
Metastatic site, number of lesions (%) | |
 Skull | 2 (0.7%) |
 Thoracic (ribs/clavicles/sternum) | 52 (45.2%) |
 Spine | 12 (10.4%) |
 Pelvis including sacral bone | 45 (39.1%) |
 Extremities | 4 (3.5%) |
Type of treatment, n (%) | |
 MDT alone | 49 (61.3%) |
 MDT + salvage RT to prostate bed and/or local recurrence and/or pelvis and regional LN | 21 (26.3%) |
 MDT + definitive RT to primary | 10 (12.5%) |
Pre-MDT PSA (ng/ml), median (range) | 1.23 (0.07–1252) |
Pre-MDT PSA-DT (month), median (range) | 4.1 (0.7–34.0) |
Dose prescription | |
 40 Gy/10 fractions (BED3: 93.3 Gy) | n = 45 (56.3%) |
 30 Gy/5 fractions (BED3: 90 Gy) | n = 17 (21.3%) |
 50.4 Gy/28 fractions (BED3: 80.6 Gy) | n = 6 (7.5%) |
 56 Gy/28 fractions (BED3: 93.3 Gy) | n = 3 (3.8%) |
 35 Gy/10 fractions (BED3: 75.8 Gy) | n = 2 (2.5%) |
 50 Gy/25 fractions (BED3: 83.3 Gy) | n = 2 (2.5%) |
 55 Gy/25 fractions (BED3: 95.3 Gy) | n = 1 (1.3%) |
 52,8 Gy/32 fractions (BED3: 81.8 Gy) | n = 1 (1.3%) |
 50 Gy/20 fractions (BED3: 91.7 Gy) | n = 1 (1.3%) |
 42 Gy/14 fractions (BED3: 84.0 Gy) | n = 1 (1.3%) |
 39 Gy/13 fractions (BED3: 78.0 Gy) | n = 1 (1.3%) |
Concomitant ADT, n (%) | 55 (68.8%) |